GRM5 and schizophrenia: Years later, it was proposed that combined treatment with A2AR and mGluR5 agonists targeting A2AR-D2R-mGluR5 heteroreceptor complexes in the ventral striatal-pallidal GABA pathway can represent a new strategy for the treatment of schizophrenia [17].